ENGLEWOOD, Colo., March 19,
2019 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI),
an innovative medical technology company specializing in the
manufacture and sale of non-invasive medical devices for pain
management, stroke rehabilitation, cardiac monitoring and
neurological diagnostics, announced today that it has reactivated
its Medicare Provider Number in an effort to also bill Medicare on
behalf of its patients.
Thomas Sandgaard, CEO said: "We
continue to expand our sales force and geographic footprint across
the US and have decided to reactivate our Medicare provider number.
Medicare continues to approve of and pay for our prescription
strength pain management technology. We believe this initiative
puts us in a strong position to procure prescriptions from more
prescribing physicians and therefore help accelerate order
growth."
About Zynex, Inc.
Zynex, founded in 1996,
markets and sells its own design of electrotherapy medical devices
used for pain management and rehabilitation; and the company's
proprietary NeuroMove device designed to help recovery of stroke
and spinal cord injury patients. Zynex is also developing a new
blood volume monitor for use in hospitals and surgery centers. For
additional information, please visit: www.zynex.com.
Safe Harbor Statement
Certain statements in this release are "forward-looking" or
projections and as such are subject to numerous risks and
uncertainties. The company makes no express or implied
representation or warranty as to the completeness of this
information or, in the case of projections, as to their
attainability or the accuracy and completeness of the assumptions
from which they are derived. Actual results may vary significantly
from the results expressed or implied in such statements. Factors
that could cause actual results to materially differ from
forward-looking statements include, but are not limited to, the
need to obtain FDA clearance and CE marking of new products, the
acceptance of new products as well as existing products by doctors
and hospitals, larger competitors with greater financial resources,
the need to keep pace with technological changes, our dependence on
the reimbursement for our products from health insurance companies,
our dependence on third party manufacturers to produce our goods on
time and to our specifications, implementation of our sales
strategy including a strong direct sales force and other risks
described in our filings with the Securities and Exchange
Commission including the "Risk Factors" section of our Annual
Report on Form 10-K for the year ended December 31,
2018 as well as Forms 10-Q, 8-K and 8-K/A, press releases and
the Company's website.
Contact:
Zynex, Inc.
(303) 703-4906
Investor Relations Contact:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/zynex-reactivates-medicare-provider-number-in-effort-to-accelerate-growth-300814398.html
SOURCE Zynex, Inc.